Why AstraZeneca Stock Was a Winner Today
Good news from the laboratory put some zip into (NASDAQ: AZN) shares on Monday. The veteran pharmaceutical company's shares enjoyed a nearly 3% lift across the trading session as a consequence, a rate that convincingly outpaced the S 500 index's 1.5% growth.
Early this morning, AstraZeneca shared the results of a phase 3 clinical trial of baxdrostat, its investigational drug for treatment-resistant hypertension (i.e., high blood pressure).
Image source: Getty Images.
Source Fool.com
